Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (181-190 of 383) with videos related to

Pageof 39
Sort By:
International Journal of Oncology|October 9, 2002
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S Farag, Kellie J Archer, Krzysztof Mrózek, et al.
Blood Advances|September 9, 2024
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosisChenyu Lin, Anand A Patel, Dezheng Huo, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Blood|April 27, 2011
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemiaMarc Buyse, Pierre Squifflet, Beverly J Lange, et al.
Blood|May 4, 2006
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B studyMichael D Radmacher, Guido Marcucci, Amy S Ruppert, et al.
Leukemia & Lymphoma|October 6, 2010
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasePeter H O'Donnell, Andrew S Artz, Samir D Undevia, et al.
Journal of Hematology & Oncology|May 15, 2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Natalie Callander, et al.
Nature Communications|June 8, 2018
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.
Pageof 39

Showing results (181-190 of 383) with videos related to

Sort By:
Pageof 39
International Journal of Oncology|October 9, 2002
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S Farag, Kellie J Archer, Krzysztof Mrózek, et al.
Blood Advances|September 9, 2024
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosisChenyu Lin, Anand A Patel, Dezheng Huo, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Blood|April 27, 2011
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemiaMarc Buyse, Pierre Squifflet, Beverly J Lange, et al.
Blood|May 4, 2006
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B studyMichael D Radmacher, Guido Marcucci, Amy S Ruppert, et al.
Leukemia & Lymphoma|October 6, 2010
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasePeter H O'Donnell, Andrew S Artz, Samir D Undevia, et al.
Journal of Hematology & Oncology|May 15, 2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Natalie Callander, et al.
Nature Communications|June 8, 2018
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.
Pageof 39